GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BrightPath Biotherapeutics Co Ltd (TSE:4594) » Definitions » EV-to-Revenue

BrightPath Biotherapeutics Co (TSE:4594) EV-to-Revenue : 25,879.25 (As of May. 10, 2024)


View and export this data going back to 2015. Start your Free Trial

What is BrightPath Biotherapeutics Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, BrightPath Biotherapeutics Co's enterprise value is 円3,053.75 Mil. BrightPath Biotherapeutics Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was 円0.12 Mil. Therefore, BrightPath Biotherapeutics Co's EV-to-Revenue for today is 25,879.25.

The historical rank and industry rank for BrightPath Biotherapeutics Co's EV-to-Revenue or its related term are showing as below:

TSE:4594' s EV-to-Revenue Range Over the Past 10 Years
Min: 6.62   Med: 224.98   Max: 43800.25
Current: 25879.25

During the past 9 years, the highest EV-to-Revenue of BrightPath Biotherapeutics Co was 43800.25. The lowest was 6.62. And the median was 224.98.

TSE:4594's EV-to-Revenue is ranked worse than
99.71% of 1036 companies
in the Biotechnology industry
Industry Median: 8.285 vs TSE:4594: 25879.25

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-10), BrightPath Biotherapeutics Co's stock price is 円58.00. BrightPath Biotherapeutics Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was 円0.00. Therefore, BrightPath Biotherapeutics Co's PS Ratio for today is 58,000.00.


BrightPath Biotherapeutics Co EV-to-Revenue Historical Data

The historical data trend for BrightPath Biotherapeutics Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BrightPath Biotherapeutics Co EV-to-Revenue Chart

BrightPath Biotherapeutics Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only 51.56 541.38 2,653.36 225.44 1,758.77

BrightPath Biotherapeutics Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 222.18 1,758.77 1,356.00 1,455.79 41,052.97

Competitive Comparison of BrightPath Biotherapeutics Co's EV-to-Revenue

For the Biotechnology subindustry, BrightPath Biotherapeutics Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BrightPath Biotherapeutics Co's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BrightPath Biotherapeutics Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where BrightPath Biotherapeutics Co's EV-to-Revenue falls into.



BrightPath Biotherapeutics Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

BrightPath Biotherapeutics Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=3053.752/0.118
=25,879.25

BrightPath Biotherapeutics Co's current Enterprise Value is 円3,053.75 Mil.
BrightPath Biotherapeutics Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BrightPath Biotherapeutics Co  (TSE:4594) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

BrightPath Biotherapeutics Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=58.00/0.001
=58,000.00

BrightPath Biotherapeutics Co's share price for today is 円58.00.
BrightPath Biotherapeutics Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BrightPath Biotherapeutics Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of BrightPath Biotherapeutics Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


BrightPath Biotherapeutics Co (TSE:4594) Business Description

Traded in Other Exchanges
N/A
Address
2-2-4 Kojimachi, Kojimachi Central Building 7th Floor, Chiyoda-ku, Tokyo, JPN
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.

BrightPath Biotherapeutics Co (TSE:4594) Headlines

No Headlines